Unilever in talks to sell food business to smaller rival McCormick

Unilever is in talks to sell its foods business to McCormick; Unilever Foods generated ~€12.9bn (~25% of group sales in 2025) and Barclays values the division at €28–31bn (~$32.4bn). McCormick’s market cap is roughly $14.5bn versus Unilever’s ~$136bn, highlighting a substantial size mismatch; McCormick shares fell up to 2.6% and Unilever was up ~1% after a prior >6% two-session drop. Talks are ongoing with no financial details and the offer was described as unsolicited; analysts suggest a Reverse Morris Trust or other complex structure could be used. Strategic rationale centers on Unilever shifting to faster-growing personal care/beauty, but execution and shareholder value creation remain uncertain.

Analysis

Unilever’s push to divest its food arm is primarily a capital-allocation event: the market will reprice UL based on how proceeds are used (buybacks, debt paydown, or bolt‑on M&A). Expect a 3–12 month window in which guidance on allocation will drive most of the stock’s upside; the kicker is whether management can convert a one‑time divestment into a durable margin story in personal care versus being judged on short‑term returns of capital.

For McCormick, the structural risk is two‑fold: financing strain from buying a much larger asset and execution risk integrating broad, low‑growth food SKUs into a spice/condiment platform. That combination typically manifests as near‑term equity weakness (funding, dilution) and multi‑quarter EBITDA shock as overlapping SKUs and plants are rationalized and divestitures are mandated by regulators.

Broader competitive dynamics create asymmetric outcomes: Kraft Heinz and other condiment specialists either become consolidation targets (if they sit on stable cash flows) or acquirers of carved‑out brands; retailers and private label players gain bargaining leverage as acquirers offload low‑margin SKUs. Also watch procurement/supply‑chain fallout — large plant rationalizations often compress supplier lead times and temporarily boost input inflation for remaining players.

Key catalysts to track in sequence: (1) formal deal terms and how consideration is split (cash vs stock) within 30–90 days, (2) announced financing path which will determine dilution vs leverage risk, and (3) regulatory feedback and any mandated carve‑outs which will alter the net asset value. The upside is re‑rating for UL on disciplined capital return; the downside is a botched, highly dilutive deal that leaves both companies structurally weaker.

Key Decisions for Investors

• Long UL equity or buy UL 9–12 month call spread (sell nearer strike to finance) — if management commits to buybacks or deleveraging, target +15–25% upside over 6–12 months. Risk: if deal collapses or proceeds are reinvested poorly, expect a 10–15% downside; keep position size 1–2% NAV and hedge with puts if exposure >2%.
• Short MKC outright or buy MKC 9–12 month puts (slightly OTM) — trade the financing/dilution and integration premium risk. Position small (0.5–1% NAV); set stop at 20% adverse move because a scrip deal or takeover rumor could spike shares.
• Pair trade: long KHC vs short MKC (equal dollar) — KHC should hold defensive pricing and could arbitrage consolidation narratives better than an acquirer stretched for capital. Timeframe 3–9 months; target relative outperformance of 10–20%.
• Event-driven catalyst play: if terms disclose significant cash consideration, buy short‑dated (30–90d) UL bonds or reduce equity hedges — cash deal reduces execution uncertainty. If consideration is equity/scrip, rotate to options hedges on MKC and reduce MKC short exposure until dilution is sized.